Figure 6 | Scientific Reports

Figure 6

From: Effective nose-to-brain delivery of exendin-4 via coadministration with cell-penetrating peptides for improving progressive cognitive dysfunction

Figure 6

Scores in the cognitive learning tests after long-term (30 times) repeated intranasal administrations to SAMR1 control and SAMP8 with progressive cognitive dysfunction. Panel A ratios of the contact time to original and novel objects during the NOR test. Panels B,C changes in the escape latency to the platform as an index of cognitive learning during the MWM test and crossing numbers across the platform area after its removal in the probe trial, respectively. Both tests were conducted at 37–38 weeks of age. Each data point represents the mean ± SEM of n = 4–8. *p < 0.05, **p < 0.01 indicate significant difference from SAMP8 receiving PBS.

Back to article page